Elevation Oncology, Inc. (ELEV) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Boston, NY, 美国. 现任CEO为 Joseph J. Ferra Jr..
ELEV 拥有 IPO日期为 2021-06-25, 34 名全职员工, 在 NASDAQ Global Select, 市值为 $21.63M.
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
